Jasper Therapeutics, INC Form 4 insider transactions

Thomas G Wiggans, a Director of Jasper Therapeutics, Inc., received 7,500 shares of common stock on July 31, 2026.

Judith Anne Shizuru, a Director of Jasper Therapeutics, Inc., received 7,500 shares of common stock on July 31, 2026.

Matthew E Ros, Chief Operating Officer of Jasper Therapeutics, Inc., purchased 881 shares of common stock on July 20, 2026.

Patrick J Crutcher, a Director of Jasper Therapeutics, Inc., purchased 888 shares of common stock on July 16, 2026.

Jasper Therapeutics' CEO and President, Jeetinder Singh Mahal, was granted 500,000 stock options with an exercise price of $1.35, vesting over several years.

Jasper Therapeutics' President, CEO, and Director Ron Martell was granted 234,000 stock options with an exercise price of $1.84, vesting over four years.

Jasper Therapeutics' Chief Operating Officer, Jeetinder Singh Mahal, was granted 90,000 stock options with an exercise price of $1.84.

Jasper Therapeutics' Chief Financial Officer, Herb Cross, was granted 90,000 stock options with an exercise price of $1.84, vesting over four years.

Jasper Therapeutics Director Thomas G. Wiggans acquired 41,000 shares of common stock and accompanying warrants in an underwritten public offering.

Svetlana Lucas, a Director at Jasper Therapeutics, acquired 20,000 shares of common stock and accompanying warrants in a public offering.

Ron Martell, President and CEO of Jasper Therapeutics, acquired 41,000 shares of common stock and accompanying warrants in a public offering.

Jasper Therapeutics Director Judith Anne Shizuru acquired 41,000 shares and warrants in a public offering, signaling confidence.

Jasper Therapeutics, Inc. Director Scott C. Brun was granted 7,500 stock options at an exercise price of $6.77, effective July 3, 2025, as part of the company's non-employee director compensation policy.

Kurt Von Emster, a Director and 10% Owner of Jasper Therapeutics, Inc., was granted an option to purchase 7,500 shares of common stock at an exercise price of $6.77 per share, effective July 3, 2025.

Judith Anne Shizuru, a Director at Jasper Therapeutics, Inc., was granted options to purchase 7,500 shares of common stock at an exercise price of $6.77 per share, effective July 3, 2025, as part of the company's non-employee director compensation policy.

Jasper Therapeutics, Inc. Director Chris Nolet was granted 7,500 stock options as part of the company's non-employee director compensation policy.

Jasper Therapeutics, Inc. Director Vishal Kapoor was granted options to purchase 7,500 shares of common stock at an exercise price of $6.77 per share, effective July 3, 2025.

Jasper Therapeutics, Inc. Director Thomas G. Wiggans was granted options to purchase 7,500 shares of common stock as part of the company's non-employee director compensation policy.

Svetlana Lucas, a director at Jasper Therapeutics, Inc., was granted options to purchase 7,500 shares of common stock at an exercise price of $6.77 per share, effective July 3, 2025.

Jasper Therapeutics, Inc. President and CEO Ron Martell was granted a stock option to acquire 234,000 shares of common stock, vesting over time, as disclosed in a recent SEC Form 4 filing.

Jasper Therapeutics, Inc.'s Chief Operating Officer, Jeetinder Singh Mahal, was granted 90,000 stock options with a $6 exercise price, vesting over four years.

Jasper Therapeutics, Inc. (JSPR) Chief Financial Officer Herb Cross was granted 90,000 stock options with an exercise price of $6, vesting over four years, as disclosed in a recent SEC Form 4 filing.

Jasper Therapeutics' Chief Medical Officer, Edwin Jonathan Tucker, was granted 90,000 stock options with a $6 exercise price, vesting over four years, as disclosed in a recent SEC Form 4 filing.

Jeetinder Singh Mahal, Chief Operating Officer of Jasper Therapeutics, acquired 50,000 stock options on February 13, 2025, according to a Form 4 filing with the SEC.

Ron Martell, CEO and Director of Jasper Therapeutics, was granted stock options for 130,000 shares on February 13, 2025.

Herb Cross, CFO of Jasper Therapeutics, acquired 50,000 stock options on February 13, 2025, according to a Form 4 filing with the SEC.

Edwin Jonathan Tucker, Chief Medical Officer of Jasper Therapeutics, acquired 50,000 stock options on February 13, 2025.

Jasper Therapeutics' Chief Operating Officer, Jeetinder Singh Mahal, exercised stock options and sold shares on December 12, 2024, under a pre-arranged 10b5-1 trading plan.

Jeetinder Singh Mahal, COO of Jasper Therapeutics, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Director Svetlana Lucas acquired 15,000 stock options in Jasper Therapeutics on June 18, 2024, according to a Form 4 filing.